Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevo tratamiento intravitreal para retinopatía diabética

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20160321001
Publicado:
01/04/2016
Caducidad:
01/04/2017
Resumen:
Una fundación española de investigación biomédica ha desarrollado un nuevo tratamiento intravitreal para retinopatía diabética. La retinopatía diabética es la principal causa de ceguera en personas mayores de 50 años en países desarrollados, y una de las principales causas de ceguera en el mundo. Esta terapia evita los efectos secundarios clínicos, presenta una mayor eficiencia y es más asequible que las terapias empleadas en la actualidad. La solución contiene una molécula antiinflamatoria esteroide y ha demostrado tener efectos beneficiosos en la retinopatía diabética al inhibir los factores desencadenantes de la inflamación en una fase experimental, consiguiendo una tasa de supervivencia más alta de las células endoteliales y una mejor conservación de la barrera hemato-retiniana. La fundación busca empresas con el fin de establecer acuerdos de licencia y colaboración técnica para su explotación.

Details

Tittle:
New intravitreal treatment for diabetic retinopathy.
Summary:
A Spanish research biomedical foundation has developed a new intravitreal treatment for diabetic retinopathy. This therapy avoids clinical side effects, shows greater efficiency and is cheaper than the therapies currently being used. This foundation is looking for companies interested in license agreement and/or technical collaboration for its exploitation.
Description:
Diabetic retinopathy (DR) is the main cause of legal blindness in people under 50 years of age in developed countries, and one of the leading causes of blindness in the world. Numerous studies show that there is an inflammatory problem which acts as the main trigger in DR, attracting leukocytes (specialized cells in the immune response) and leading eventually to failure and loss of vascular endothelium, as well as increased vascular permeability (causing edema) and increased platelet aggregation (contributing to vessel obliteration and retinal ischemia). This allows using new intravitreal drugs that may be able to avoid activation of molecular inflammatory pathways, and at the same time may achieve a better preservation of retinal vessels that conform the hemato-retinal barrier / blood-retinal barrier (BRB).
The Spanish research foundation has developed a solution that has been formulated for intravitreal injection, which contains a non steroidal anti-inflammatory molecule and has shown experimentally to have beneficial effects on DR by inhibiting inflammatory triggering factors in an experimental phase, achieving a higher survival rate of endothelial cells and higher preservation of the BRB. Therefore, it could act by preventing the appearance of diabetic macular edema (DME) in patients with high risk of developing it, or solving the DME that is already underway, but it could also avoid the onset of retinal ischemia and progression towards more severe stages of the disease.
The foundation is seeking pharmaceutical companies with particular focus in diabetic retinopathy for technical cooperation and or license agreement in order to develop new pharmaceutical treatments for DR adapted to the scientific evidence associated with the metabolic and molecular pathways involved in this disease.
This technology has been developed and tested with animal model of DR.
Advantages and Innovations:
· Low cost of obtaining the active ingredient
· Experimental evidence of its ability to act simultaneously in various molecular pathways involved in pathogenesis of DR
· Better cost-effectiveness than the treatments currently used
· The currently biological intravitreal drugs available for the treatment block angiogenesis induced by type A vascular endothelial growth factor. However no one of these drugs modifies the clinical course of the disease since they do not prevent microangiopathy nor solves ischemia or alteration of capillary/permeability that occur in DR and, in addition, they have a high cost.
· No side effects. Steroids currently used produce high rate of side effects, especially, increase the intraocular pressure and induce cataract formation. Also there is no evidence of better results than biological treatments.





Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent application

Partner sought

Type and Role of Partner Sought:
The foundation is looking for pharmaceutical laboratories in the field of ophthalmology intravitreal, which seek to develop a new therapy with international potential market for the treatment of diabetic retinopathy, willing to sign a license agreement and/or technical/research cooperation for the development, and subsequently commercial exploitation, of this technology.
-Type of partner sought: companies.
-Specific area of activity of the partner: pharmacy, health, ophthalmology.
-Task to be performed: licensing and/or joint further developments. Adaptation of the developed technology to the specific requirement of the ophthalmology pharmaceutic market.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos
06001013 Tecnología médica / ingeniería biomédica